These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
217 related articles for article (PubMed ID: 30666679)
1. Polymyxin B clinical outcomes: A prospective study of patients undergoing intravenous treatment. Mattos KPH; Gouvêa IR; Quintanilha JCF; Cursino MA; Vasconcelos PENS; Moriel P J Clin Pharm Ther; 2019 Jun; 44(3):415-419. PubMed ID: 30666679 [TBL] [Abstract][Full Text] [Related]
2. Skin hyperpigmentation following intravenous polymyxin B treatment associated with melanocyte activation and inflammatory process. Mattos KPH; Cintra ML; Gouvêa IR; Ferreira LÁ; Velho PENF; Moriel P J Clin Pharm Ther; 2017 Oct; 42(5):573-578. PubMed ID: 28497462 [TBL] [Abstract][Full Text] [Related]
3. Parenteral polymyxin B use in patients with multidrug-resistant gram-negative bacteremia and urinary tract infections: a retrospective case series. Pastewski AA; Caruso P; Parris AR; Dizon R; Kopec R; Sharma S; Mayer S; Ghitan M; Chapnick EK Ann Pharmacother; 2008 Sep; 42(9):1177-87. PubMed ID: 18664609 [TBL] [Abstract][Full Text] [Related]
4. Combination therapy with polymyxin B for the treatment of multidrug-resistant Gram-negative respiratory tract infections. Sobieszczyk ME; Furuya EY; Hay CM; Pancholi P; Della-Latta P; Hammer SM; Kubin CJ J Antimicrob Chemother; 2004 Aug; 54(2):566-9. PubMed ID: 15269195 [TBL] [Abstract][Full Text] [Related]
5. Polymyxin B for the treatment of multidrug-resistant pathogens: a critical review. Zavascki AP; Goldani LZ; Li J; Nation RL J Antimicrob Chemother; 2007 Dec; 60(6):1206-15. PubMed ID: 17878146 [TBL] [Abstract][Full Text] [Related]
6. Colistin and polymyxin B in critical care. Michalopoulos A; Falagas ME Crit Care Clin; 2008 Apr; 24(2):377-91, x. PubMed ID: 18361952 [TBL] [Abstract][Full Text] [Related]
7. Polymyxin B: a new strategy for multidrug-resistant Gram-negative organisms. Yuan Z; Tam VH Expert Opin Investig Drugs; 2008 May; 17(5):661-8. PubMed ID: 18447592 [TBL] [Abstract][Full Text] [Related]
8. Framework for optimisation of the clinical use of colistin and polymyxin B: the Prato polymyxin consensus. Nation RL; Li J; Cars O; Couet W; Dudley MN; Kaye KS; Mouton JW; Paterson DL; Tam VH; Theuretzbacher U; Tsuji BT; Turnidge JD Lancet Infect Dis; 2015 Feb; 15(2):225-34. PubMed ID: 25459221 [TBL] [Abstract][Full Text] [Related]
9. Outcome of intravenous and inhaled polymyxin B treatment in patients with multidrug-resistant gram-negative bacterial pneumonia. Ding P; Li H; Nan Y; Liu C; Wang G; Cai H; Yu W Int J Antimicrob Agents; 2024 Oct; 64(4):107293. PubMed ID: 39094752 [TBL] [Abstract][Full Text] [Related]
10. Epidemiology and outcome of infections with carbapenem-resistant Gram-negative bacteria treated with polymyxin B-based combination therapy. Crusio R; Rao S; Changawala N; Paul V; Tiu C; van Ginkel J; Chapnick E; Kupfer Y Scand J Infect Dis; 2014 Jan; 46(1):1-8. PubMed ID: 24206450 [TBL] [Abstract][Full Text] [Related]
11. Personalizing Polymyxin B Dosing Using an Adaptive Feedback Control Algorithm. Lakota EA; Landersdorfer CB; Nation RL; Li J; Kaye KS; Rao GG; Forrest A Antimicrob Agents Chemother; 2018 Jul; 62(7):. PubMed ID: 29760144 [TBL] [Abstract][Full Text] [Related]
12. Polymyxin B nephrotoxicity and efficacy against nosocomial infections caused by multiresistant gram-negative bacteria. Ouderkirk JP; Nord JA; Turett GS; Kislak JW Antimicrob Agents Chemother; 2003 Aug; 47(8):2659-62. PubMed ID: 12878536 [TBL] [Abstract][Full Text] [Related]
13. Multi-drug resistant gram negative infections and use of intravenous polymyxin B in critically ill children of developing country: retrospective cohort study. Siddiqui NU; Qamar FN; Jurair H; Haque A BMC Infect Dis; 2014 Nov; 14():626. PubMed ID: 25430979 [TBL] [Abstract][Full Text] [Related]
14. Colistin versus polymyxin B for the treatment of patients with multidrug-resistant Gram-negative infections: a systematic review and meta-analysis. Vardakas KZ; Falagas ME Int J Antimicrob Agents; 2017 Feb; 49(2):233-238. PubMed ID: 27686609 [TBL] [Abstract][Full Text] [Related]
15. Clinical use of intravenous polymyxin B for the treatment of patients with multidrug-resistant Gram-negative bacterial infections: An evaluation of the current evidence. Falagas ME; Kyriakidou M; Voulgaris GL; Vokos F; Politi S; Kechagias KS J Glob Antimicrob Resist; 2021 Mar; 24():342-359. PubMed ID: 33486122 [TBL] [Abstract][Full Text] [Related]
16. To B or not to B, that is the question: is it time to replace colistin with polymyxin B? Kassamali Z; Danziger L Pharmacotherapy; 2015 Jan; 35(1):17-21. PubMed ID: 25346395 [TBL] [Abstract][Full Text] [Related]
17. Clinical Use of Polymyxin B. Rigatto MH; Falci DR; Zavascki AP Adv Exp Med Biol; 2019; 1145():197-218. PubMed ID: 31364080 [TBL] [Abstract][Full Text] [Related]
18. Predictors of polymyxin B treatment failure in Gram-negative healthcare-associated infections among critically ill patients. Ismail B; Shafei MN; Harun A; Ali S; Omar M; Deris ZZ J Microbiol Immunol Infect; 2018 Dec; 51(6):763-769. PubMed ID: 28716359 [TBL] [Abstract][Full Text] [Related]
19. Salvage treatment of pneumonia and initial treatment of tracheobronchitis caused by multidrug-resistant Gram-negative bacilli with inhaled polymyxin B. Pereira GH; Muller PR; Levin AS Diagn Microbiol Infect Dis; 2007 Jun; 58(2):235-40. PubMed ID: 17350201 [TBL] [Abstract][Full Text] [Related]
20. Polymyxin antibiotics for gram-negative infections. Arnold TM; Forrest GN; Messmer KJ Am J Health Syst Pharm; 2007 Apr; 64(8):819-26. PubMed ID: 17420197 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]